News | Wearables

November 3, 2017 — VitalConnect Inc. announced the fourth and final Series C closing, bringing the total Series C round ...

Home November 03, 2017
Home
Technology | FFR Technologies

Acist Medical Systems Inc., a Bracco Group Company, announced the global launch of its Acist RXi Mini System, the next-generation system of its RXi Rapid Exchange FFR System. The RXi Mini System debuted at the 29th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver.

Home November 03, 2017
Home
The Watchman LAA occluder PREVAIL Trial 5-year results were presented at the 2017 TCT meeting.
Feature | Atrial Fibrillation

November 2, 2017 – Five-year results from the PREVAIL Trial comparing left atrial appendage closure (LAAC) with the ...

Home November 02, 2017
Home
The B. Braun Sequent Please drug-eluting balloon.
Feature | Drug-Eluting Balloons

November 2, 2017 — The treatment of in-stent restenosis (ISR) remains challenging in clinical practice. The DARE (Drug ...

Home November 02, 2017
Home
News | Chronic Total Occlusion (CTO)

November 2, 2017 — Crossing the occlusion with a guidewire is often the most challenging part of chronic total occlusion ...

Home November 02, 2017
Home
News | Stents Drug Eluting

OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, Oct. 29-Nov. 2 in Denver. The results provide fresh insights into the optimal treatment of patients with acute coronary syndrome (ACS) using the COMBO Dual Therapy Stent.

Home November 01, 2017
Home
News | Stents Bifurcation

The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion failure at one year compared with provisional stenting (PS) in the treatment of true distal bifurcation lesions of the left main artery, according to a large-scale randomized trial.

Home November 01, 2017
Home
News | Cardiac Diagnostics

Analytics 4 Life announced it will be presenting new clinical data on the company's ongoing Coronary Artery Disease Learning and Algorithm Development (CADLAD) study at the Transcatheter Cardiovascular Therapeutics (TCT) 2017 scientific symposium, Oct. 29-Nov. 2 in Denver.

Home November 01, 2017
Home
News | Radiation Dose Management

James A. Brink, M.D., FACR, chair of the American College of Radiology (ACR) Board of Chancellors, met with the House Committee on Science, Space and Technology Subcommittee on Energy to urge more research on low-dose medical radiation effects to inform future safety practices. He also told the Committee that medical imaging and radiation oncology save lives.

Home November 01, 2017
Home
News | Heart Valve Technology

Analysis of the PARTNER 2A trial and the SAPIEN-3 Intermediate Risk registry found transcatheter aortic valve replacement (TAVR) to be highly cost-effective compared with surgical aortic valve replacement (SAVR) in intermediate surgical risk patients with aortic stenosis.

Home November 01, 2017
Home
News | Cath Lab

November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strategy ...

Home November 01, 2017
Home
News | Embolic Protection Devices

October 31, 2017 — The VAMPIRE 3 study evaluated if the selective use of distal filter protection might decrease the ...

Home October 31, 2017
Home
News | Heart Valve Technology

Edwards Lifesciences Corp. announced new data demonstrating substantial economic advantages of the Edwards Sapien 3 transcatheter aortic heart valve for patients suffering from severe, symptomatic aortic stenosis (AS) who are at intermediate risk for open-heart surgery. Results of the economic analysis, which is the first-of-its-kind report on intermediate-risk patients, were presented as a late-breaking clinical trial at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, Oct. 29-Nov. 2 in Denver.

Home October 31, 2017
Home
News | Stents Bioresorbable

Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target lesion failure (TLF).

Home October 31, 2017
Home
News | Stents Bioresorbable

October 31, 2017 — The U.S. Food and Drug Administration (FDA) issued a warning to healthcare providers that interim ...

Home October 31, 2017
Home
Subscribe Now